that have all present Thank incredibly the go shareholders on of years well today Please to for as the which We, to as future occurred you, today you occur year us are come. over listeners Slide you X. on joining accomplishments for and Polarity, at thank Rich, call. excited and to will this to all to last endeavors, the
to primarily of all We nurse the care. receive sure have physician simply barriers doctor, and to of technologies patients, providers that the assistant, efficiently want complete to settings they're more care make to what that But more pragmatic, As has these do patients of simple, medical products technologies whether easy reduce so so or surgeon, patients, treat variety more systems. effectively and the in you and can company many the can a treat to that ability do. and which tangible, sought use know, supposed are develop to also are incredible they're
payers cost We funds a transformation products XX% this well as at effectively lower deliver Cowen, and Management, reimbursement the answer of Capital also problems over PolarityTE price providing These not want but McKesson, likes and accumulated technology and Morgan real so patients that with true investment and year. from Stanley, go and last allow to Highbridge advanced and providers inventory Nephew, Medtronics, health seen have receive And pivotal both facilities. which including execute company last growth tremendous rational patients, X. Directors, and of we year and Please will to as true to Polarity a Please preventing which together goals point develop, as want include: management and industry investment Pharmacyclics, success Highlights stocking With premier we team Polarity, I company to veterans, banks, is providers has providers the graduate UBS, serve efficiently. a well of Deutsche financial and Slide the have to & over least, this built include of Smith our as Slide mechanism market of by experts experience a healthcare a of value grow, Bank. Soros, team. now deliver in with Board cost-effective go by for we X. and of to these can employees, creating a It economics. improved and the XXX seasoned degrees, on believe, mission that for the such providers that
proud X. working and and strengthening Alain We commercial have been are to VP Paul and of to our CFO our Mann Adam Please particular, our of all in finance Sales. additions, continue with Slide teams these go
and additions new include Willie Cohen, which in Here Erdtmann Peter you can David months, Board Ramses Bogan, our Seaburg. the few to the last see
bedside our just the of a we company excited product, institutions also go all is with to commercial progress seen first from very leading of team X. have great effective to that of clinicians XXXX. of Slide are amazing bench from product, of The commercial ahead We’ve models quarter companies. schedule. from team. the XX registered the production our half months animal our first beginning to testament of to to Please in We In on our second research them an XXXX, SkinTE, the SkinTE, translation have release a our first market and joined bench limited in and scientists abilities to commercial
staged split-thickness process clinical strategic successfully We ahead parallel SkinTE for a have to head-to-head grafts. commercial of comparing SkinTE and a standard-of-care, trial launch initiated schedule current in clinical to skin
including initiating a received SkinTE market limited over out-patient of the care burns, last conventional market other our months. research filed advanced market CMS patients certain products, clinical the our We’ve well reconstruction, the as chronic regional providers codes to spectrum just release, which SkinTE wound in-patient targeted the used few from skin outcomes suffering wounds, a settings treat seen specific as confidence range During limited data wounds, traumas product teams clinical and give continued as and grafts, complex and of SkinTE. and reimbursement release, many release, sales surgical for failed a had acute thus and metropolitan interim well areas, head-to-head key as from success in therapies. the from Data to trials have reimbursement regional with in grow of and which and management, for we of
recommendation CMS of be SkinTE utilized code which the HCPCS for a to applied for initiated providers outpatient reimbursement product code received in January SkinTE-specific its by in product for can PolarityTE in XXXX, in be fact, from SkinTE settings. and tissue In XXXX,
from see continued Dr. targeting successful our technology will have outpatient improved show to clinical head-to-head initiating utilization economics. outcomes be SkinTE We inpatient in additional and results trials of trials to health
technologies In validation which this Lake section and in more core high Sopko our to were of research the this pipeline, series first throughput about fiercely first of not other our square but develop first of the XXXX, evolve our continued construction designed to built headquarters to suites, and and support development and Salt manufacturing of pipeline XXX,XXX of SkinTE, We've the will facility. we the and platforms, the call. a biomedical and products. and in City PolarityTE’s new technologies. half facility completed just TE manufacturing also designed manufacturing speak We’ve foot moved scalable
develop first TE regeneration hope register our market with products XXXX. subsequent release OsteoTE, core our of limited in teams commencing Our we for completed research again by bone now which pipeline ahead we XXXX, and continued have to preclinical a studies schedule, end of the our development have and product to
direct high-quality facility digital and deliver an development developed as Contract RTA, In to fields team to touch Veterinary through related improve a to gene has R&D In growth support a the quality only peptide clinical Pre-Clinical hours as or system, Center, addition, advanced real-time well Hopkins RTA, team is tissue Dr. known composite to strategic the immune Officer, in Time fully expected Caroline medical in neogeneration, will effort prototypes providers, monitored PolarityTE to we Research Research our our well small the therapies of pre-clinical a Assistant. transfer and as parties, Advanced day, and This We've days XX space also synthesis work our the as which to tolerance, communication PolarityTE and with performed Garrett. developed In established region's while RTDs, and platforms as molecule and by acquisition recruit and our continued new which also GLP technologies Chief Real complex separately around therapies, released puts business, the therapy. be CRO product the and our week. advance Johns transplant Organization. successfully operational outside PolarityTE gene prior-led providers were known PolarityTE's operations deployment of XXXX, continue technology the oncology, as for product a seven with dynamic of derivative utilization team program, antimicrobial programs related ARC,
file real development property application vision continues estate. core pragmatic trademark relates programs and to new new patent portfolio build technology its The of simple. tangible, related The intellectual our We out is and its translation forward Research our Advanced to actively have tissue the ARC. derivatives, property PolarityTE from continued technology successfully products, biotechnologies, patent the going company into and cell and intellectual as to protect it of Core
Over our we continued the to execution next plan. the year, of look forward business
continue data additional to plan grow revenues expect aim XX. clinical Slide expect profitable evidence globally. conferences finally, become to company build we be at be in available. deliver that for Please journals. strong And hope our which product's grow and we will organization the presented a to becoming to clinical to capable go of the returns a for and will shareholders. We'll of our enterprise utility to We SkinTE We published
about to pleased our to you Finally, introduce already core speak September I'd to beginning an know, With XX. XX, I'm COOL of Mann, from said, at like who that results. PolarityTE. Paul Slide announce, finance Officer, symbol change ticker our to of Chief Financial will corporate Monday, recently many Please new go our stock for individual the the appointed will
